Our data clearly demonstrated that inhibition of p-eIF2α de-phosphorylation using the eIF2α inhibitor salubrinal resulted in higher levels of STIM1, CHOP and ATF4 expression, and significantly abrogated the induction of p-ERK1/2 in pevonedistat-treated ALL cells. The gene discussed is MAPK3; the disease is acute lymphoblastic leukemia.